Iptacopan hydrochloride by Novartis for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): Likelihood of Approval

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis).

M1 Kliniken AG decides to start share buyback – Biotech Investments

M1 Kliniken AG / Key word(s): Share Buyback M1 Kliniken AG decides to start share buyback 26-Apr-2024 / 11:06 CET/CEST Disclosure of an inside information

April 27, 2024

Popular nasal decongestant doesn’t actually relieve congestion, FDA experts say

WASHINGTON — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, according

September 12, 2023

Researchers show how communication networks in the tumor microenvironment promote cancer growth

Tumors consist of both the actual, malignant cancer cells and healthy, non-transformed cells in the immediate environment.

July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.